The investigators evaluate the efficacy and safety of intravenous administration of nicorandil as adjuncts to reperfusion treatment in acute ST-segment elevation acute myocardial infarction (STEMI) patients undergoing primary percutaneous coronary intervention (PCI).
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
1,500
6 mg nicorandil iv. just before coronary intervention, 6mg/h ivgtt. up to 48h after coronary intervention
placebo iv. just before coronary intervention, ivgtt. up to 48h after coronary intervention
Zhongshan Hospital
Shanghai, Shanghai Municipality, China
Major adverse cardiac events
cardiac death, myocardial reinfarction, target vessel revascularization, unplanned hospitalization for heart failure
Time frame: 12 month after primary PCI
Rate of slow re-flow/no-reflow
final coronary flow in the culprit artery
Time frame: 3 minutes after primary PCI
Rate fo complete ST-segment resolution
ST-segment resolution \>50% in ECG
Time frame: 2 hours after primary PCI
Cardiac death
Cardiac death
Time frame: 12 months after primary PCI
Myocardial reinfarction
Myocardial reinfarction
Time frame: 12 months after primary PCI
Target vessel revascularization
Target vessel revascularization
Time frame: 12 months after primary PCI
Unplanned hospitalization for heart failure
Unplanned hospitalization for heart failure
Time frame: 12 months after primary PCI
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.